Steinmetz O M, Panzer U, Stahl R A K, Wenzel U O
Department of Medicine, Division of Nephrology, University Hospital of Hamburg Eppendorf, Hamburg, Germany.
Eur J Clin Invest. 2006 Aug;36(8):519-27. doi: 10.1111/j.1365-2362.2006.01668.x.
Dyslipdemia is a common complication of chronic kidney disease (CKD) and contributes to high cardiovascular morbidity and mortality of CKD patients. Experimental studies have demonstrated that lipids induce glomerular and tubulointerstitial injury and that lipid-lowering treatments ameliorate renal injury. Therapy with statins not only has the potential to lower cardiovascular morbidity and mortality in patients with CKD but also to slow progression of renal disease. Whereas the guidelines for treatment of hyperlipidaemia in nonrenal patients are based on prospective, randomized, placebo-controlled mega-trials, such data are not available for CKD patients. This review outlines the limited information currently available on the effect of statins among patients with CKD and summarizes the ongoing randomized trials designed to address this question.
血脂异常是慢性肾脏病（CKD）的常见并发症，也是CKD患者心血管疾病高发病率和高死亡率的原因之一。实验研究表明，脂质可导致肾小球和肾小管间质损伤，而降脂治疗可改善肾脏损伤。他汀类药物治疗不仅有可能降低CKD患者的心血管疾病发病率和死亡率，还能减缓肾病进展。非肾病患者的高脂血症治疗指南基于前瞻性、随机、安慰剂对照的大型试验，而CKD患者尚无此类数据。本综述概述了目前关于他汀类药物对CKD患者影响的有限信息，并总结了旨在解决这一问题的正在进行的随机试验。
